Suppr超能文献

氯沙坦与依那普利对易卒中型高血压大鼠脑水肿和蛋白尿的影响

Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats.

作者信息

Blezer E L, Nicolay K, Koomans H A, Joles J A

机构信息

Department of Nephrology and Hypertension, University Medical Centre, Utrecht, The Netherlands.

出版信息

Am J Hypertens. 2001 Jan;14(1):54-61. doi: 10.1016/s0895-7061(00)01231-0.

Abstract

Stroke-prone spontaneously hypertensive rats (SHRSP), subjected to high NaCl, show severe hypertension, organ damage, and early death. Preventive treatment with angiotensin II type 1 (AT1) receptor antagonists is known to be effective. Previously, we found that angiotensin converting enzyme (ACE) inhibition could reduce cerebral edema when treatment was started after manifestation of either proteinuria or cerebral edema. In this study AT1 receptor blockade was started at the same time points to evaluate whether this had an effect superior to ACE inhibition. SHRSP drank 1% NaCl. Group 1 served as controls. Group 2 and 3 rats were started on losartan and enalapril after proteinuria exceeded 40 mg/day. Group 4 and 5 rats were started on losartan and enalapril after the first observation of cerebral edema with T2-weighted magnetic resonance imaging scans. In controls, median survival was 54 days (range, 35 to 80 days) after the start of salt loading. With early-onset losartan and enalapril, survival increased to 305 days (range, 184 to 422 days) and 320 days (range, 134 to 368 days) (both P < .01 v group 1). Cerebral edema formation was prevented in all but two rats, one from each treatment modality. Development of proteinuria was markedly reduced. With late-onset treatment with losartan and enalapril, survival was 290 days (range, 120 to 367 days) and 264 days (range, 154 to 319 days) (both P < .01). Both losartan and enalapril decreased cerebral edema to baseline levels. Ultimately cerebral edema reoccurred, despite continued treatment, in 75% of the rats. Systolic blood pressure did not decrease after losartan treatment, but, similarly to early-onset treatment, decreased transiently after enalapril treatment. Cerebral edema and proteinuria were prevented and reduced in SHRSP treated with either an AT1 receptor antagonist or an ACE inhibitor. Survival was markedly and similarly prolonged by both treatments, whether initiated directly before or after development of cerebral edema. In rats where treatment was initiated after manifestation of cerebral edema, both cerebral edema and proteinuria reappeared despite continued treatment. Apparently, when hypertension is sustained, reappearance of target organ damage may not be entirely dependent on angiotensin.

摘要

易患中风的自发性高血压大鼠(SHRSP)摄入高氯化钠后会出现严重高血压、器官损伤和早期死亡。已知用1型血管紧张素II(AT1)受体拮抗剂进行预防性治疗是有效的。此前,我们发现,在蛋白尿或脑水肿出现后开始治疗时,抑制血管紧张素转换酶(ACE)可减轻脑水肿。在本研究中,在相同时间点开始进行AT1受体阻断,以评估其效果是否优于ACE抑制。SHRSP饮用1%的氯化钠溶液。第1组作为对照组。蛋白尿超过40mg/天后,第2组和第3组大鼠开始使用氯沙坦和依那普利。在首次通过T2加权磁共振成像扫描观察到脑水肿后,第4组和第5组大鼠开始使用氯沙坦和依那普利。在对照组中,开始盐负荷后中位生存期为54天(范围为35至80天)。早期开始使用氯沙坦和依那普利后,生存期分别延长至305天(范围为184至422天)和320天(范围为134至368天)(两者与第1组相比P均<0.01)。除两只大鼠(每种治疗方式各一只)外,所有大鼠的脑水肿形成均得到预防。蛋白尿的发展明显减少。晚期开始使用氯沙坦和依那普利治疗后,生存期分别为290天(范围为120至367天)和264天(范围为154至319天)(两者P均< .01)。氯沙坦和依那普利均将脑水肿降至基线水平。最终,尽管持续治疗,75%的大鼠脑水肿再次出现。氯沙坦治疗后收缩压未降低,但与早期治疗类似,依那普利治疗后收缩压短暂降低。用AT1受体拮抗剂或ACE抑制剂治疗的SHRSP的脑水肿和蛋白尿得到预防和减轻。两种治疗均显著且相似地延长了生存期,无论在脑水肿出现之前还是之后开始治疗。在脑水肿出现后开始治疗的大鼠中,尽管持续治疗,脑水肿和蛋白尿仍再次出现。显然,当高血压持续存在时,靶器官损伤的再次出现可能并不完全依赖于血管紧张素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验